Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$118.55 USD

118.55
2,612,544

+1.71 (1.46%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $118.55 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Company News for Jul 19, 2023

by Zacks Equity Research

Companies In The News Are: SYF, NVS, SCHW, PNC.

Zacks Equity Research

Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised

by Zacks Equity Research

Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.

Zacks Equity Research

Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Q2 2023 Earnings Season Gathers Pace

by Zacks Equity Research

Q2 2023 Earnings Season Gathers Pace.

Mark Vickery headshot

Q2 Earnings Week Brings Us Tesla, Netflix & More

by Mark Vickery

Aside from a handful of Wall Street banks and other industry leaders, Q2 numbers are out this week for the first of the FAANGs and Tesla.

Zacks Equity Research

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Why Novartis (NVS) Might Surprise This Earnings Season

by Zacks Equity Research

Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?

by Zacks Equity Research

When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.

Zacks Equity Research

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%

by Zacks Equity Research

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.

Zacks Equity Research

Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study

by Zacks Equity Research

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.

Zacks Equity Research

Novartis (NVS) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Novartis (NVS) closed at $97.16, marking a +0.63% move from the previous day.

Zacks Equity Research

Cigna (CI) to Add Three Biosimilars to NPF, Enable Cost Savings

by Zacks Equity Research

Cigna (CI) plans to integrate three cost-effective biosimilars within NPF in a bid to offer varied treatment options for Americans and solidify its pharmacy business.

Zacks Equity Research

Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study

by Zacks Equity Research

Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Zacks Equity Research

Novartis (NVS) Entresto Patent Faces Setback, Stock Down

by Zacks Equity Research

Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.

Zacks Equity Research

Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study

by Zacks Equity Research

Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.

Zacks Equity Research

Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug

by Zacks Equity Research

Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.

Zacks Equity Research

AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results

by Zacks Equity Research

While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.

Zacks Equity Research

Here's Why You Should Add Alkermes (ALKS) to Your Portfolio

by Zacks Equity Research

Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.

Zacks Equity Research

Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus

by Zacks Equity Research

Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.

Zacks Equity Research

Roche (RHHBY) Announces Positive Long-Term Data on SMA Drug

by Zacks Equity Research

Roche's (RHHBY) SMA drug Evrysdi maintains its efficacy and safety profile in children with type 1 SMA after four years of treatment.

Zacks Equity Research

Aurinia (AUPH) Up on Paving the Way for a Potential Buyout

by Zacks Equity Research

Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.

Zacks Equity Research

Immunome (IMNM) Surges on Merger Agreement With Morphimmune

by Zacks Equity Research

Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC

by Zacks Equity Research

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.

Zacks Equity Research

Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly

by Zacks Equity Research

Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.

Zacks Equity Research

Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe

by Zacks Equity Research

Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk.